Northfield Labs Reports Verified Data From Troubled Phase III PolyHeme Study
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Northfield Laboratories is moving ahead with plans to file a BLA for its investigational red blood cell substitute PolyHeme, despite protocol violations that triggered a data verification process and a planned safety analysis to gain insight on myocardial infarction data